Meta-analysis quantifies lifestyle factors accounting for RA incidence

(HealthDay)—Nearly one-third of rheumatoid arthritis (RA) incidence is attributed to smoking, excess body mass index, and low alcohol consumption, according to a study published online Jan. 26 in&nbsp

Updated on: May 08,2024 6

Meta-analysis quantifies lifestyle factors accounting for RA incidence

(HealthDay)—Nearly one-third of rheumatoid arthritis (RA) incidence is attributed to smoking, excess body mass index, and low alcohol consumption, according to a study published online Jan. 26 in&nbsp

Updated on:May 08,2024 6

Risankizumab safe, effective at 52 weeks for psoriatic arthritis

by Lori SolomonRisankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently publishe

Updated on: June 01,2024 7

Risankizumab safe, effective at 52 weeks for psoriatic arthritis

by Lori SolomonRisankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently publishe

Updated on:June 01,2024 7

Aerobic exercise may cut fatigue in rheumatoid arthritis

(HealthDay)—Aerobic land-based exercise may be helpful in treating fatigue in patients with rheumatoid arthritis (RA), according to a meta-analysis published in the August issue ofArthritis Care

Updated on: March 24,2024 13

Aerobic exercise may cut fatigue in rheumatoid arthritis

(HealthDay)—Aerobic land-based exercise may be helpful in treating fatigue in patients with rheumatoid arthritis (RA), according to a meta-analysis published in the August issue ofArthritis Care

Updated on:March 24,2024 13

Do you know a child with a peanut allergy? The FDA just approved a treatment drug

by David J. NealCredit: CC0 Public DomainKids who live with peanut allergies, which can have consequences ranging from annoying to fatal, now have an approved form of pharmaceutical relief, the FDA an

Updated on: April 15,2024 20

Do you know a child with a peanut allergy? The FDA just approved a treatment drug

by David J. NealCredit: CC0 Public DomainKids who live with peanut allergies, which can have consequences ranging from annoying to fatal, now have an approved form of pharmaceutical relief, the FDA an

Updated on:April 15,2024 20

COVID-19 can cause severe inflammation in the brain

by Albert Ludwigs University of FreiburgGraphical Abstract. Credit:Immunity(2021). DOI: 10.1016/j.immuni.2021.06.002Both during and after infection with the Coronavirus SARS-CoV-2, pa

Updated on: April 10,2024 18

COVID-19 can cause severe inflammation in the brain

by Albert Ludwigs University of FreiburgGraphical Abstract. Credit:Immunity(2021). DOI: 10.1016/j.immuni.2021.06.002Both during and after infection with the Coronavirus SARS-CoV-2, pa

Updated on:April 10,2024 18

A new approach to study autoimmune diseases

by Indiana Biosciences Research InstituteVenn diagrams of risk genes expressed in the target tissues of the fourautoimmune diseases (type 1 diabetes, systemic lupus erythematosus, multiple sclerosis,

Updated on: March 25,2024 14

A new approach to study autoimmune diseases

by Indiana Biosciences Research InstituteVenn diagrams of risk genes expressed in the target tissues of the fourautoimmune diseases (type 1 diabetes, systemic lupus erythematosus, multiple sclerosis,

Updated on:March 25,2024 14

m6A mRNA modification potentiates Th17 functions to inflame autoimmunity

by Science China PressLoss of METTL3 in Th17 cells facilitated SOCS family RNA stability, inhibited IL-6/STAT3 mediated IL-17A and CCR5 expression, which in turn impeding Th17 cells differentiati

Updated on: April 16,2024 11

m6A mRNA modification potentiates Th17 functions to inflame autoimmunity

by Science China PressLoss of METTL3 in Th17 cells facilitated SOCS family RNA stability, inhibited IL-6/STAT3 mediated IL-17A and CCR5 expression, which in turn impeding Th17 cells differentiati

Updated on:April 16,2024 11

Takayasu arteritis, ulcerative colitis co-occurrence rate high

(HealthDay)—Takayasu arteritis (TAK) has a high rate of co-occurrence and genetic overlap with ulcerative colitis (UC), according to a study published in the August issue ofArthritis & Rheum

Updated on: March 24,2024 20

Takayasu arteritis, ulcerative colitis co-occurrence rate high

(HealthDay)—Takayasu arteritis (TAK) has a high rate of co-occurrence and genetic overlap with ulcerative colitis (UC), according to a study published in the August issue ofArthritis & Rheum

Updated on:March 24,2024 20

Prevalence of knee OA lower with menopausal hormone therapy

(HealthDay)—For postmenopausal women, the prevalence of knee osteoarthritis is lower with menopausal hormone therapy (MHT) use, according to a study published online Dec. 21 inMenopause.Jae Hyun

Updated on: May 26,2024 5

Prevalence of knee OA lower with menopausal hormone therapy

(HealthDay)—For postmenopausal women, the prevalence of knee osteoarthritis is lower with menopausal hormone therapy (MHT) use, according to a study published online Dec. 21 inMenopause.Jae Hyun

Updated on:May 26,2024 5

A bacterial toxin turning cells into swiss cheese

by Kanazawa UniversityResearchers from Kanazawa University developed a novel tool to study how the innate immune system fights bacterial toxins. They purified the pore-forming toxin Monalysin fro

Updated on: May 05,2024 20

A bacterial toxin turning cells into swiss cheese

by Kanazawa UniversityResearchers from Kanazawa University developed a novel tool to study how the innate immune system fights bacterial toxins. They purified the pore-forming toxin Monalysin fro

Updated on:May 05,2024 20

Rituximab retreatment at clinical relapse cost-effective in RA

(HealthDay)—Rituximab retreatment at clinical relapse is at least as cost-effective as a more intensive regimen in longstanding rheumatoid arthritis (RA), according to a study published in the July is

Updated on: April 08,2024 18

Rituximab retreatment at clinical relapse cost-effective in RA

(HealthDay)—Rituximab retreatment at clinical relapse is at least as cost-effective as a more intensive regimen in longstanding rheumatoid arthritis (RA), according to a study published in the July is

Updated on:April 08,2024 18

Study finds antibody-associated vasculitis characteristics and treatments vary across lifespan

by American College of RheumatologyMedications ever received by patients with granulomatosis with polyangiitis and microscopic polyangiitis stratified by age at diagnosis. Credit: The Association

Updated on: May 08,2024 5

Study finds antibody-associated vasculitis characteristics and treatments vary across lifespan

by American College of RheumatologyMedications ever received by patients with granulomatosis with polyangiitis and microscopic polyangiitis stratified by age at diagnosis. Credit: The Association

Updated on:May 08,2024 5